BidaskClub upgraded shares of Cara Therapeutics (NASDAQ:CARA) from a sell rating to a hold rating in a research note issued to investors on Saturday.
Several other equities research analysts also recently commented on CARA. ValuEngine downgraded shares of Cara Therapeutics from a hold rating to a sell rating in a research report on Friday. Canaccord Genuity set a $25.00 target price on shares of Cara Therapeutics and gave the stock a buy rating in a research report on Saturday, August 5th. Piper Jaffray Companies set a $27.00 target price on shares of Cara Therapeutics and gave the stock a buy rating in a research report on Saturday, August 5th. Needham & Company LLC reiterated a buy rating and set a $23.00 target price on shares of Cara Therapeutics in a research report on Wednesday, October 4th. Finally, Zacks Investment Research downgraded shares of Cara Therapeutics from a buy rating to a hold rating in a research report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $25.17.
Shares of Cara Therapeutics (CARA) opened at $12.60 on Friday. Cara Therapeutics has a 1 year low of $8.62 and a 1 year high of $28.50.
Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). During the same period last year, the business posted ($0.42) EPS. equities analysts predict that Cara Therapeutics will post -1.84 earnings per share for the current year.
In other news, CEO Derek T. Chalmers sold 16,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total value of $202,560.00. Following the transaction, the chief executive officer now owns 1,066,292 shares in the company, valued at approximately $13,499,256.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.50% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Gotham Asset Management LLC acquired a new position in shares of Cara Therapeutics in the 2nd quarter worth approximately $448,000. Vanguard Group Inc. increased its stake in shares of Cara Therapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,107,874 shares of the biopharmaceutical company’s stock valued at $17,050,000 after acquiring an additional 164,247 shares in the last quarter. C WorldWide Group Holding A S increased its stake in shares of Cara Therapeutics by 76.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 291,341 shares of the biopharmaceutical company’s stock valued at $3,988,000 after acquiring an additional 126,330 shares in the last quarter. Swiss National Bank bought a new stake in shares of Cara Therapeutics in the 2nd quarter valued at $651,000. Finally, FMR LLC increased its stake in shares of Cara Therapeutics by 27.7% in the 2nd quarter. FMR LLC now owns 1,198,812 shares of the biopharmaceutical company’s stock valued at $18,450,000 after acquiring an additional 260,036 shares in the last quarter. Hedge funds and other institutional investors own 58.80% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Cara Therapeutics (CARA) Raised to Hold at BidaskClub” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/cara-therapeutics-cara-raised-to-hold-at-bidaskclub.html.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.